Manufacturing

Articles

Avantor plans to increase its single-use manufacturing footprint by 30% and double its cleanroom space in the US and Europe.

Avantor to Increase Global Capacity for Single-Use Technologies

Vertex and CRISPR have amended their collaboration agreement to include the development, manufacture, and commercialization of CTX001, an investigational CRISPR/Cas9-based gene editing therapy for sickle cell disease and transfusion-dependent beta-thalassemia.

Vertex Pharmaceuticals and CRISPR Therapeutics Amend Agreement for $1.1 Billion

Catalent plans to add cryogenic capabilities to its facility in Philadelphia, which will strengthen its ability to cryogenically preserve cell therapies and other biological materials.

Catalent to Add Cryogenic Capabilities to Support Cell and Gene Therapy Development

The ATMPS and Ori Biotech collaboration aims to improve visibility and reporting of cell and gene therapy manufacturing through a pre-integrated data solution.

ATMPS and Ori Biotech Collaborate on Integrated Digital Platform for Cell and Gene Therapy

The UK's National Horizons Centre has been confirmed as a National Training Centre that will deliver on-site advanced therapies and vaccine manufacturing specific training.

National Horizons Centre to Provide ATMP and Vaccine Manufacture Training

This agreement enhances GSK’s investment in cell and gene therapy manufacturing in the UK for clinical trials.

GSK Expands Clinical Trial Manufacturing Capacity for Cell and Gene Therapy at Catapult UK Facility

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

More work is needed to ensure the rising demand for cell and gene therapy manufacturing capacity and required skilled workforce can be met in Europe.

Meeting CGT Demand

Under the terms of the acquisition, OXGENE will become a fully owned subsidiary of WuXi Advanced Therapies, WuXi AppTec’s cell and gene therapy contract testing, development, and manufacturing organization business unit.

WuXi AppTec Acquires OXGENE to Increase Cell and Gene Therapy Offerings

The site will house development and GMP production capacities for cell and gene therapies, next-generation vaccines, and biopharmaceuticals, to support clients from early clinical trials through commercialization.

Celonic to Establish New Cell and Gene Therapy Production Site in Switzerland

The expansion, to be completed in April 2021 aims to increase the CDMO’s viral-vector production capacity in Spain.

Manufacturing, Gene Therapies